These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 8831743

  • 1. [Report of nationwide questionnaire: intraperitoneal chemotherapy for advanced ovarian cancer based on clinical results--reports of 5th "Gynecologic Intraperitoneal Chemotherapy Study Group" meeting].
    Umezawa S, Shimizu Y, Takizawa K, Nishimura H, Hatae M, Sasaki K, Yoshikawa H.
    Gan To Kagaku Ryoho; 1996 Sep; 23(10):1305-11. PubMed ID: 8831743
    [Abstract] [Full Text] [Related]

  • 2. Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer.
    Almadrones L.
    Clin J Oncol Nurs; 2007 Apr; 11(2):211-6. PubMed ID: 17573270
    [Abstract] [Full Text] [Related]

  • 3. Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer.
    Naumann RW, Sukumvanich P, Edwards RP.
    Gynecol Oncol; 2009 Jul; 114(1):37-41. PubMed ID: 19410281
    [Abstract] [Full Text] [Related]

  • 4. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Berry E, Matthews KS, Singh DK, Buttin BM, Lurain JR, Alvarez RD, Schink J.
    Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
    [Abstract] [Full Text] [Related]

  • 5. Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer.
    Lan C, Li Y, Liu J.
    Gynecol Oncol; 2009 Jul; 114(1):42-7. PubMed ID: 19398124
    [Abstract] [Full Text] [Related]

  • 6. Treatment of ovarian cancer with intraperitoneal chemotherapy.
    Hydzik C.
    Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):15-20. PubMed ID: 19856603
    [Abstract] [Full Text] [Related]

  • 7. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?
    Petignat P, du Bois A, Bruchim I, Fink D, Provencher DM.
    Crit Rev Oncol Hematol; 2007 May; 62(2):137-47. PubMed ID: 17188887
    [Abstract] [Full Text] [Related]

  • 8. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T, Klasa-Mazurkiewicz D, Emerich J, Kobierski J.
    Acta Obstet Gynecol Scand; 2009 May; 88(4):463-7. PubMed ID: 19235559
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Advanced cancer of the ovary: intraperitoneal chemotherapy as a new therapeutical option.
    Fiorentini G, Filippeschi M, Turrisi G, Mambrini A, Giannessi PG, D'Alessandro M, Rossi S, Dentico P, Guadagni S, Cantore M, Madrigali A.
    In Vivo; 2009 May; 23(2):317-21. PubMed ID: 19414421
    [Abstract] [Full Text] [Related]

  • 11. Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?
    Tummala MK, Alagarsamy S, McGuire WP.
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1135-47. PubMed ID: 18588458
    [Abstract] [Full Text] [Related]

  • 12. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
    Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D.
    Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
    [Abstract] [Full Text] [Related]

  • 13. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
    Royer B, Delroeux D, Guardiola E, Combe M, Hoizey G, Montange D, Kantelip JP, Chauffert B, Heyd B, Pivot X.
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):415-21. PubMed ID: 17503047
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer.
    Zeimet AG, Reimer D, Radl AC, Reinthaller A, Schauer C, Petru E, Concin N, Braun S, Marth C.
    Anticancer Res; 2009 Jul; 29(7):2803-8. PubMed ID: 19596965
    [Abstract] [Full Text] [Related]

  • 17. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL, Meisner BC, Armstrong DK, Frick KD.
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [Abstract] [Full Text] [Related]

  • 18. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P.
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [Abstract] [Full Text] [Related]

  • 19. ACOG Committee Opinion No. 396. Intraperitoneal chemotherapy for ovarian cancer.
    American College of Obstetricians and Gynecologists.
    Obstet Gynecol; 2008 Jan; 111(1):249. PubMed ID: 18165421
    [Abstract] [Full Text] [Related]

  • 20. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.
    Fung-Kee-Fung M, Provencher D, Rosen B, Hoskins P, Rambout L, Oliver T, Gotlieb W, Covens A, IP Chemotherapy Working Group/Society of Gynecologic Oncologists of Canada.
    Gynecol Oncol; 2007 Jun; 105(3):747-56. PubMed ID: 17368522
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.